Ponzetto C, Guerrasio A, Rosso C, Avanzi G, Tassinari A, Zaccaria A, LoCoco F, Foa R, Basso G, Abate M L
Dipartimento di Scienze Biomediche e Oncologia Umana, Universita' di Torino, Italy.
Br J Haematol. 1990 Sep;76(1):39-44. doi: 10.1111/j.1365-2141.1990.tb07834.x.
The Philadelphia chromosome (Ph1) is present in 95% of chronic myelogenous leukaemias (CML) and 15% of acute lymphoblastic leukaemias (ALL). This cytogenetic marker is due to a t(9;22) translocation, which causes a rearrangement of the ABL oncogene. In order to better define the relationship between type of genomic rearrangement, variant ABL protein expressed and haematological phenotype, a series of Ph1-positive acute leukaemias, both myeloblastic (AML) and lymphoblastic, and several CML lymphoid blast crises have been analysed at the DNA and protein level. The results confirm the presence of the ABL protein P210 in all cases of CML, ALL and AML positive for rearrangement in the bcr region of chromosome 22, and, surprisingly, in one AML case apparently negative for bcr rearrangement. The ABL protein P190 was found to be present only in cases of ALL negative for bcr rearrangement. Polymerase chain reaction (PCR) analysis of the types of 9/22 junctions present in the mRNA of CML lymphoid blast crises showed no evidence of 'ALL-type' transcripts.
费城染色体(Ph1)存在于95%的慢性粒细胞白血病(CML)和15%的急性淋巴细胞白血病(ALL)中。这种细胞遗传学标志物归因于t(9;22)易位,它导致ABL癌基因重排。为了更好地界定基因组重排类型、所表达的变异ABL蛋白与血液学表型之间的关系,已在DNA和蛋白质水平对一系列Ph1阳性急性白血病(包括髓细胞性白血病(AML)和淋巴细胞性白血病)以及几例CML淋巴细胞母细胞危象进行了分析。结果证实,在所有22号染色体bcr区域重排阳性的CML、ALL和AML病例中均存在ABL蛋白P210,令人惊讶的是,在1例bcr重排显然为阴性的AML病例中也存在。发现ABL蛋白P190仅存在于bcr重排阴性的ALL病例中。对CML淋巴细胞母细胞危象mRNA中存在的9/22连接类型进行的聚合酶链反应(PCR)分析未显示“ALL型”转录本的证据。